Intense Radiotherapy Slows Prostate Cancer Growth

Adding stereotactic ablative radiotherapy (SABR) to standard treatment slowed 6-month disease progression in men with hormone-sensitive metastatic prostate cancer, allowing them to delay androgen deprivation therapy, according to findings from the phase II ORIOLE trial. Larger studies are needed to determine if SABR, alone or combined with immunotherapies, can prevent new metastases in some patients.